Investor Jordi Visser argues that Eli Lilly, a pharmaceutical company with 150 years of proprietary metabolic disease data, is positioned to be a major AI winner. Unlike AI hardware providers like Nvidia, Lilly combines AI with unique healthcare data and blockbuster obesity and diabetes treatments, potentially transforming it into a leading AI-powered drug discovery platform. This shift could significantly increase its valuation beyond traditional pharma metrics. The company's AI initiatives include partnerships with Nvidia and Google’s AlphaFold, signaling a strong AI infrastructure within its drug development process. While risks remain, Lilly’s deep data moat could make it a dominant player in the AI and healthcare intersection.
